Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
FDA Clears Dupixent for Chronic Hives After Decade Without New Options
Copy link
Facebook
Email
Notes
More

FDA Clears Dupixent for Chronic Hives After Decade Without New Options

FDA greenlights dupilumab for chronic spontaneous urticaria in patients 12 and older with symptoms unresponsive to antihistamines

Naveen Sankar S's avatar
Naveen Sankar S
Apr 21, 2025
∙ Paid

Share this post

Just Healthcare
Just Healthcare
FDA Clears Dupixent for Chronic Hives After Decade Without New Options
Copy link
Facebook
Email
Notes
More
Share
Generated image

Topline

Dupilumab (Dupixent) has received FDA approval as an add-on treatment for chronic spontaneous urticaria (CSU) in patients aged 12 and older who continue to experience symptoms despite using H1 antihistamines.

Study Details

Chronic spontaneous urticaria (CSU) is a distressing inflammatory skin condition marked by recurring, unpredictable hives and i…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More